Unlock this StockReport nowClick to Unlock

Oncoarendi Therapeutics SA Share Price

OAT PLN11.9 -0.1  -0.8%

Relative Strength (%)
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
Margin of Safety (beta)
Screens Passed 2
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2013 2014 2015 2016 2017 2018 TTM 2019E 2020E CAGR / Avg
Revenue PLNm
Operating Profit PLNm
Net Profit PLNm
EPS Reported PLN
EPS Normalised PLN
EPS Growth %
PE Ratio x
Operating Margin %
Op. Cashflow ps PLN
Capex ps PLN
Free Cashflow ps PLN
Dividend ps PLN
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc PLNm
Working Capital PLNm
Net Fixed Assets PLNm
Net Debt PLNm
Book Value PLNm
Average Shares m
Book Value ps PLN +131.8%

FINANCIAL BRIEF: For the three months ended 31 March 2019, Oncoarendi Therapeutics SA revenues increased 5% to PLN1K. Net loss increased from PLN560K to PLN1.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Labor & Related Expenses in SGA increase from PLN210K to PLN505K (expense), Remuneration increase from PLN74K to PLN170K (expense). more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score
Other Ratios
Leverage (ttm) Total -Intang +Pension
Gross Gearing %
Net Gearing %
Cash / Assets %
Recent History
Latest interim period (ended 31st Mar '19) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2019
31st Dec 2020

Price Target: PLN45.8
(+284.91% above Price)
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: n/a (PLN) (PLN) (PLN) (PLN) (PLN) (PLN)
Consensus Estimate
1m Change
3m Change
1 broker Broker Consensus Trend
Broker Recommendations for Oncoarendi Therapeutics SA
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 0 0 0 1 0

Named Brokers and Analysts
Trigon Dom Maklerski ,

Profile Summary

OncoArendi Therapeutics SA (OAT) is a Poland-based biopharmaceutical company dedicated to discovering, developing and commercializing therapeutics for neoplastic and inflammatory diseases. The Companys business model is strictly focused on drug discovery and development, with its core strength in medicinal chemistry and preclinical biology, enhanced by scientific collaborations with the key opinion leaders in specific disease areas.

Directors: Krzysztof Laskowski (CSU) , Marcin Szumowski (CMG) 50, Mariusz Gromek (VSU) , Slawomir Broniarek (FID) , Marta Borkowska (COO) , Karolina Dzwonek (VPR) , Adam Golebiowski (VPR) , Jacek Olczak (VPR) , Nicolas Beuzen (VBD) , Pawel Dobrzanski (SDR) , Henryk Gruza (SUB) , Grzegorz Mironski (SUB) , Piotr Zolkiewicz (SUB) 35,

No. of Employees: 88 No. of Shareholders: n/a

Last Annual December 31st, 2018
Last Interim March 31st, 2019
Incorporated January 4, 2017
Public Since April 19, 2018
Shares in Issue 13,670,000
Free Float 10.0m (73.3%)
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange Warsaw Stock Exchange
Eligible for an ISA? a SIPP?

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2019.

Should you buy OAT

Access OAT Analytics Now!

Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis